We are excited to share that Biocytogen will participate as a vendor at the Preclinical Pharmacology Studies and Translational Medicine for Drug Discovery and Development (PBSS) on May 12, 2025, in Foster City (San Francisco Bay Area), CA. This summit will provide an overview of animal pharmacology models used in drug development, covering oncology, autoimmune, neurological, and metabolic diseases. Join us for insightful discussions and expert perspectives—see you in Foster City!
What is the Preclinical Pharmacology Studies and Translational Medicine for Drug Discovery and Development?
The Preclinical Pharmacology Studies and Translational Medicine for Drug Discovery and Development is hosted by the Pharmaceutical & BioScience Society (PBSS). This full-day workshop will provide a comprehensive overview of animal pharmacology models for drug development across oncology, autoimmune, neurological, and metabolic diseases. Led by in vivo pharmacology experts, the workshop features case studies and discussions on model selection, study design, and clinical relevance.
Event Overview
Date: May 12, 2025 · 8:45 AM – 5:00 PM PDT
Venue: Crowne Plaza Foster City-San Mateo, 1221 Chess Dr, Foster City, CA
Event Schedule
The Preclinical Pharmacology Studies and Translational Medicine for Drug Discovery and Development (PBSS) Workshop will feature expert-led sessions on animal pharmacology models, study design, clinical translatability, breaks, lunch, and a dedicated vendor show. For the full schedule and session details, please refer to PBSS.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the PBSS in Foster City, CA!
